T1	p 82 89	control
T2	p 124 141	type 1 diabetes .
T3	p 242 278	diagnosis with type 1 diabetes ( T1D
T4	p 344 367	diagnosis with standard
T5	p 513 525	subcutaneous
T6	p 562 619	24 patients , 8-18 years old , with newly diagnosed T1D .
T7	p 634 643	evaluated
T8	p 706 722	diagnosis of T1D
T9	p 1394 1415	pump-treated subjects
T10	p 1494 1511	subjects reported
T11	i 6 26	Insulin pump therapy
T12	i 320 332	insulin pump
T13	i 368 390	multiple daily insulin
T14	i 485 558	MDI therapy with continuous subcutaneous insulin therapy ( pump therapy )
T15	i 932 950	continuous glucose
T16	i 1118 1130	pump therapy
T17	i 1614 1626	insulin pump
T18	i 1808 1820	pump therapy
T19	o 73 89	glycemic control
T20	o 183 218	residual insulin secretory capacity
T21	o 391 401	injections
T22	o 741 758	insulin secretion
T23	o 770 816	by mixed-meal-stimulated C-peptide secretion ,
T24	o 896 919	glycosylated hemoglobin
T25	o 958 1037	data , insulin utilization , anthropometric measures , and patient satisfaction
T26	o 1104 1114	Initiation
T27	o 1191 1244	mixed-meal tolerance test-stimulated C-peptide values
T28	o 1353 1369	glycemic control
T29	o 1423 1452	time spent with normoglycemia
T30	o 1455 1472	better mean HbA1c
T31	o 1534 1546	satisfaction
T32	o 1657 1673	glycemic control
T33	o 1680 1700	well tolerated , and
T34	o 1725 1745	patient satisfaction
T35	o 1844 1868	residual ?-cell function